ArticlePolymers2018
Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy.
Article in Polymers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Contemporary Aspects of Designing Marine Polysaccharide Microparticles as Drug Carriers for Biomedical Application.Pharmaceutics · 2023Review
- The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges.Microorganisms · 2023Review
- Novel Fucoidan Pharmaceutical Formulations and Their Potential Application in Oncology-A Review.Polymers · 2023Review
- A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.Drug delivery and translational research · 2023Review
- Co-Delivery of D-LAK Antimicrobial Peptide and Capreomycin as Inhaled Powder Formulation to Combat Drug-Resistant Tuberculosis.Pharmaceutical research · 2023Article
- Fucoidan in Pharmaceutical Formulations: A Comprehensive Review for Smart Drug Delivery Systems.Marine drugs · 2023Review
- Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations.Regenerative biomaterials · 2023Review
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- Targeting Intracellular Mycobacteria Using Nanosized Niosomes Loaded with Antibacterial Agents.Nanomaterials (Basel, Switzerland) · 2021Article
- The effect of ethanol on the habit andAsian journal of pharmaceutical sciences · 2021Article
- Stability and In Vitro Aerodynamic Studies of Inhalation Powders Containing Ciprofloxacin Hydrochloride Applying Different DPI Capsule Types.Pharmaceutics · 2021Article
- Formulation and In Vitro and In Silico Characterization of "Nano-in-Micro" Dry Powder Inhalers Containing Meloxicam.Pharmaceutics · 2021Article
- Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages.Drug delivery and translational research · 2020Article
- Hydrothermal Processing ofMarine drugs · 2020Article
- Article
- Inhalable Spray-Dried Chondroitin Sulphate Microparticles: Effect of Different Solvents on Particle Properties and Drug Activity.Polymers · 2020Article
- Multifunctional Nanocarriers for Lung Drug Delivery.Nanomaterials (Basel, Switzerland) · 2020Review
- Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery.Pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The pulmonary delivery of antitubercular drugs is a promising approach to treat lung tuberculosis. This strategy not only allows targeting the infected organ instantly, it can also reduce the systemic adverse effects of the antibiotics. In light of that, this work aimed at producing fucoidan-based inhalable microparticles that are able to associate a combination of two first-line antitubercular drugs in a single formulation. Fucoidan is a polysaccharide composed of chemical units that have been reported to be specifically recognised by alveolar macrophages (the hosts of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.